- Home
- MDGL vs FMS Comparison
MDGL vs FMS Comparison
Compare MDGL & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | FMS |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | Germany |
| Employees | N/A | 108165 |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 11.6B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDGL | FMS |
|---|---|---|
| Price | $508.53 | $23.20 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 12 | 2 |
| Target Price | ★ $674.45 | $30.00 |
| AVG Volume (30 Days) | 262.9K | ★ 609.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.57% |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,133,000.00 | N/A |
| Revenue This Year | $58.39 | N/A |
| Revenue Next Year | $48.55 | $3.83 |
| P/E Ratio | ★ N/A | $15.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $284.02 | $20.02 |
| 52 Week High | $615.00 | $28.87 |
Technical Indicators
Market Signals| Indicator | MDGL | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 56.12 |
| Support Level | $498.59 | $22.50 |
| Resistance Level | $540.72 | $23.36 |
| Average True Range (ATR) | 17.55 | 0.31 |
| MACD | 3.74 | 0.12 |
| Stochastic Oscillator | 70.79 | 64.69 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.